Abstract. Methods to implement two-stage designs in two-treatment, two-sequence, and two-period crossover bioequivalence studies have only recently been developed. The two-stage methods have so far only been described for a targeted study power of 80%. Since it is sometimes desirable to increase the targeted power to 90%, this study identifies sets of alphas that work for the recently developed two-stage methods while controlling type I error rates around 5% for assumed geometric mean test/reference ratios of 0.90 and 0.95 at targeted power of 90%, and provides a characterization of the methods in terms of the resulting sample sizes and power. Depending on the actual variability and the chosen sample size at stage 1, the actual power will be between 83% and 100%. The previously characterised methods at target power 80% as well as 90% result in trivial inflation of type 1 error, but the type 1 error inflation at 90% target powers with decreased alpha at the second stage result in slightly less inflation. These results may be useful for applicant wishing to achieve increased power in bioequivalence trials without a penalty for type I error rates.
INTRODUCTION
Bioequivalence trials typically involve testing of two products (test and reference) against each other in a two-period, twosequence crossover trial. Primary metrics are C max (maximum observed plasma concentration) and area under the concentration-time curve. On basis of a normal linear model on the logarithmic scale with the fixed factors treatment, sequence, period, and subject, a 90% confidence interval for the test/ reference ratio is derived. The two products are said to be bioequivalent when the confidence interval is contained within the interval 0.8-1.25. Using a 90% confidence interval corresponds to an alpha of 5%. For a given true variability (coefficient of variation, CV) and true test/reference geometric mean ratio (in the following referred to as T/R) it is relatively easy to calculate the number of subjects necessary to achieve any desired power. However, the true ratios are never known. Occasionally, one can look up such estimates in the literature or even conduct pilot trials to estimate them before conducting confirmatory trials.
As an alternative, it has been proposed that sequential designs could be used where initially a limited number of subjects are evaluated and then, if necessary, more subjects are included before a final evaluation. Controlling the type I error rate (patient's risk; the chance of approving a bioinequivalent product) is a challenge for such approaches. Potvin et al. (1) invented four sequential design algorithms to deal with this issue and demonstrated with a series of simulation studies how these design algorithms performed in terms of type I errors and power for various levels initial sample size (N 1 ), when T/R is 0.95 and the target power is 0.8. The algorithms, called method B, C, and D, use different levels of alpha for stages 1 and 2 and are illustrated in Figs. 2, 3, and 4 of Potvin's work. Methods C at T/R00.95 and D at T/R00.90 are identical with the exception that the second alpha value is 0.0294 in method C and 0.0280 in method D. Potvin et al. recommended methods B and C when a T/R of 0.95 is assumed. Later, in a subsequent publication, Montague et al. (2) extended the studies to a T/R of 0.90 and concluded that under this circumstance method D was performing better.
There are situations when it is desirable to increase power above 80%. This is for example when there is considerable uncertainty about the T/R ratio and the CV. A simple example is when a company for some commercial reason simply considers 80% too little. A more tricky example is a study on dry powder inhalers with two active pharmaceutical ingredients. A subject inhaling deeper or more efficiently than average will, all other factors equal, inhale more of both ingredients. For such a subject, the residuals for both ingredients in the separate analyses could be positive [and vice versa for poor inhalers]. In addition, there may be poorly understood differences in regional absorption for the two active ingredients. Thus, the chance of showing bioequivalence for both active pharmaceutical ingredients will be lower than the chance of showing bioequivalence for one of them; but we have no way of dimensioning the trial well due to residuals that can correlate in unknown and unpredictable ways.
Obviously, the type I error rate as well as power vary with the alpha's employed at the two stages. The purpose of this study is thus to identify combinations of alpha that preserve the overall type I error rate at 5% when the target power is 90% rather than 80% as studies by Potvin et al. and Montague et al. and to characterise the methods in terms of study power. This is done for T/R ratios of 0.95, for which Potvin recommend methods B and C, and 0.90 when method D was recommended. Since method C applied at T/R 0.95 and D applied at T/R 0.90 differ only in the second alpha, there is no real distinction between them when a new second alpha is identified for a simulation scenario. In the following, I will therefore refer to them as method C/D.
MATERIALS AND METHODS
Simulation software was programmed in C on a Windows 32-bit platform by the author, and implemented all of the equations given by Potvin (1) and used by Montague (2) . The compiler used was MinGW 3.4.2 interfaced via DevC++ 4.9.9.2. For random number generation, the Mersenne Twister algorithm was used; to generate Gaussian numbers, a Box-Muller transform was used. The software was validated against the results published by Potvin and Montague. The software allowed implementation of methods B and C/D at any level of targeted power and second alpha. For each scenario, 1,000,000 trials were simulated and type I error rate and power was estimated along with sample size diagnostics (average, median, 5th percentile and 95th percentile). Scenarios included sample sizes at stage 1 (N 1 ) of 12, 24, 36, 48, and 60 and CV levels of 10%, 20%, 30%, 40%, 50%, 60%, 70%, and 80%.
RESULTS
Using the original stage 1 alpha levels from Potvin's algorithms, the following alpha levels for stage 2 were found to preserve overall type I errors at 5%:
Method B at T/R00.95, α 2 00.0284 Method C/D at T/R00.95, α 2 00.0274 Method C/D at T/R00.90, α 2 00.0269
These values are identified from the interpolation method described elsewhere (3); basically, the overall type I error rate is an approximately linear function of the α 2 around the range of α 2 values that correspond to 5% overall alpha. On this basis, linear regression can be used to infer a level of α 2 , which gives an overall alpha of 5%.
Using the alpha values exactly as specified in Potvin's paper will result in inflated type I errors (data not shown) when the target power is 90%. Table I presents performance diagnostics in terms of type I errors and power when these alpha levels are applied to method B at T/R00.95, method C/D at T/R00.95 and method C/D at T/R00.90 (these are the assumed geometric test/ reference ratios used for calculation of power and stage 2 sample size). Information about sample sizes (average sample size, median, and 5th and 95th percentile) can be found in the Electronic Supplementary Material.
DISCUSSION
The tables present alpha levels that allow type I errors to be preserved at 5% at a targeted power of 90% and give prospective sponsors/applicants information about the overall chance of showing bioequivalence and the corresponding sample sizes needed under these circumstances. The underscored type I errors represent the highest values identified for the three methods, and they can be considered statistically insignificantly above 5% (2) . Like the works of Potvin and Montague (1, 2) , the proposed α 2 levels inflate type I error rates slightly but insignificantly.
Even though a power of 90% is targeted, the actual power will-due to the nature of the two-stage algorithmoccasionally be lower than 90%. In this study, the lowest power obtained was 82.7% and 82.6% for method B and C/D (T/R 0.95), respectively, while it was 83.9% for method C/D which was used at T/R 0.90. These figures are observed when the CV is maximal and the initial sample size minimal.
The figures also illustrate that situations do exist when it is not a good idea to start with just N 1 012 subjects. Consider for example the case of CV00.3 for method B (T/R 0.95). If the applicant starts with N 1 012, then the average sample size is around 61 subjects whereas if the applicant starts with N 1 0 24 the average sample size is around 50 and even a bit lower for N 1 036. In all scenarios, the power exceeds 86%. The example shows that in some cases, significant human exposure can be avoided (and presumably money saved) by avoiding low initial sample sizes. It should be emphasised, though, that the true CV is never known and sometimes no qualified guess about its value is available prior to initiation of the trial. This could be used as an argument why N 1 012 should be avoided.
There is some potential room for improvement or refinement of these methods. It may be possible that the alphas of the methods can be further optimised so as to preserve type I errors at 5% while minimising the sample sizes. From an ethical and commercial standpoint, this would be desirable. In addition, it would be relevant to investigate if imbalance (different subject numbers in the two sequences; this is impossible for applicants to actually control in practice) causes inflation of the type I error rates, and likewise it would be relevant to extend these methods to parallel study designs which are also valid from a regulatory standpoint and sometimes used by sponsors.
CONCLUSION
It is possible to identify alpha levels for the second stage which keep the overall type I error rate controlled at 5% for the methods derived from Potvin's work (1) when the target power is 90%. These alpha levels are 0.0284 for method B at T/R00.95, 0.0274 for method C/D at T/R00.95 and 0.0269 for method C/D at T/R00.90. In these scenarios, power will generally be between 83% and 100% all depending on the variability and initial sample size. The results also indicate that for ethical reasons one should not uncritically use a low sample size in stage 1 (e.g., N 1 012), since the average total number of subjects required and exposed to the investigational product may be lower if a higher initial sample size (e.g., N 1 024) is chosen.
